BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang W, Liu L, Zhang M, Zhang F, Peng C, Zhang B, Chen J, Li L, He J, Xiao J, Feng Y, Wang X, Xiong A, Yang L, Zou X, Yu Y, Zhuge Y. Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome. J Clin Transl Hepatol 2021;9:345-52. [PMID: 34221920 DOI: 10.14218/JCTH.2020.00124] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Teschke R, Vongdala N, Quan NV, Quy TN, Xuan TD. Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update. Int J Mol Sci 2021;22:10419. [PMID: 34638760 DOI: 10.3390/ijms221910419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang X, Zhang W, Zhang M, Zhang F, Xiao J, Yin Q, Han H, Li T, Lin G, Zhuge Y. Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Hepatol Int 2022. [PMID: 35023026 DOI: 10.1007/s12072-021-10293-5] [Reference Citation Analysis]